{"id":"f5f4a3ecedea","type":"article","url":"https://hartvaat.nl/2026/05/09/subcut-hf-ii-subcutane-furosemide-thuis-verlaagt-opnameduur-met-5-5-dagen-na-har/","title":"SUBCUT HF II: subcutane furosemide thuis verlaagt opnameduur met 5,5 dagen na hartfalenopname","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["furosemide","heart-failure-2026","hfref"],"journal":"Heart Failure 2026 (Late-Breaking Science)","doi":"https://www.prnewswire.com/news-releases/results-of-the-randomized-controlled-trial-of-at-home-subcutaneous-diuretic-therapy-for-heart-failure-associated-edema-to-be-presented-at-heart-failure-2026-302760746.html","source_url":"https://doi.org/https://www.prnewswire.com/news-releases/results-of-the-randomized-controlled-trial-of-at-home-subcutaneous-diuretic-therapy-for-heart-failure-associated-edema-to-be-presented-at-heart-failure-2026-302760746.html","authors":["Ross T. Campbell","Mark C. Petrie","SUBCUT HF II Investigators"],"significance":8,"published":"2026-05-11","source_date":"2026-05-09","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/","https://hartvaat.nl/kennis/hartfalen/diuretica-bij-hartfalen/"],"congress":"heart-failure-2026","summary_en":"SUBCUT HF II (UK, 20 NHS sites, n=170) compared at-home subcutaneous furosemide via the Lasix ONYU patch-pump (80 mg over 5h) versus continued inpatient IV furosemide in patients admitted with HF-associated edema. At-home treatment yielded +4 days alive-and-out-of-hospital at 30 days (p<0.001) and reduced index hospitalization length by 5.5 days (p<0.001), sustained at 60 days, with equivalent safety. Lasix ONYU was FDA-approved October 2025; SUBCUT HF II provides the supporting RCT evidence. Direct implications for cardiology capacity planning.","created":"2026-07-03T10:32:54Z","updated":"2026-07-03T13:31:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"SUBCUT HF II — gerandomiseerd, open-label, multicentrisch in 20 NHS-ziekenhuizen in het VK, 170 patiënten — vergeleek vroege ontslag met subcutane furosemide thuis (Lasix ONYU; 80 mg over 5 uur via patch-pomp) met voortgezette intraveneuze furosemide in het ziekenhuis. Het primaire eindpunt — dagen levend en buiten het ziekenhuis (DAOH) op 30 dagen — was 4 dagen gunstiger met thuisbehandeling (p<0,001); de duur van de indexopname daalde met 5,5 dagen (p<0,001). De winst bleef behouden op 60 dagen. Veiligheid en secundaire eindpunten waren equivalent. Conclusie: voor geselecteerde patiënten met persisterende congestie die intraveneuze diuretica nodig hebben, is thuisbehandeling met subcutane furosemide effectief, veilig en logistiek significant beter. De Lasix ONYU patch-pomp werd in oktober 2025 door de FDA goedgekeurd; SUBCUT HF II levert het ondersteunende RCT-bewijs. Onmiddellijke implicaties voor capaciteitsplanning op de cardiologie-afdeling en hartfalenpolicliniek.","abstract_original":"BACKGROUND: Persistent congestion at discharge in patients hospitalised with heart failure (HF) is associated with worse outcomes; inpatient intravenous diuretic therapy is often prolonged because at-home parenteral options are limited. SUBCUT HF II evaluated whether a novel subcutaneous furosemide formulation (Lasix ONYU; 80 mg infused over 5 hours via patch-pump) administered at home is non-inferior — and operationally superior — to inpatient intravenous furosemide. METHODS: Investigator-sponsored, multicentre, open-label, randomised controlled trial across 20 UK National Health Service hospitals. 170 patients admitted for HF and requiring ongoing intravenous loop diuretic therapy were randomised 1:1 to (a) early discharge with at-home subcutaneous furosemide via Lasix ONYU or (b) continued inpatient intravenous furosemide. The primary endpoint was days alive and out of hospital (DAOH) at 30 days. RESULTS: Patients randomised to at-home subcutaneous furosemide had 4 more days alive and out of hospital at 30 days than the inpatient comparator (p<0.001), with index-hospitalization length of stay reduced by 5.5 days (p<0.001). The DAOH benefit was sustained at 60 days. Safety and key secondary endpoints supported equivalence to in-hospital treatment. CONCLUSIONS: At-home subcutaneous furosemide via Lasix ONYU is an effective and safe alternative to inpatient intravenous diuresis in patients with HF-associated edema, materially shortening hospitalization without compromising safety or efficacy. Lasix ONYU received FDA approval in October 2025; SUBCUT HF II provides the supporting randomised evidence. Results presented at Heart Failure 2026 (Barcelona, 9 May 2026). Peer-reviewed publication forthcoming."}